Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by Boomskidon Jun 22, 2023 6:37pm
273 Views
Post# 35510238

Pump & Dump?

Pump & Dump?
Dr. Deborah Rathjen and Dr. Mario Saltarelli agreed to join the Biodexa board. If they knew that xB3 was no good, then why did they agree to do that? There are a number of possibilities.
 
Thought processes following the principles of Occam's razor would suggest that they agreed to join Biodexa because they expected to make money through the development of xB3 therapeutics, either within Biodexa or in a private company that may have acquired the xB3 Platform.
 
Or, could it have been that Midatech represented a way out of it all and by joining Biodexa, when it was eventually discovered that xB3 was no good, they would be absolved of accusations of fraud by claiming that they didn’t know there was a problem with xB3?
 
Or did Rathjen, Saltarelli, Midatech, Ladenburg Thalmann and the placee all know that xB3 was no good and that what they were interested in was promoting Biodexa as a pump and dump?
 
And as I previously asked, if xB3 is no good, and if Rathjen knew it, then do Chiesi, J&J, Neuramedy and others have grounds for taking legal action for fraud against Rathjen and Bioasis?

If you’re going to make the unsupportable statement that xB3 is no good then you’d best see how your emotional conclusions fit with what we know.
 
Some of you guys have your heads up an unnamed nether part.
 
Stop being so ridiculous.
 
jd
<< Previous
Bullboard Posts
Next >>